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Abstract
Friedreich’s ataxia, the most frequent progressive autosomal recessive disorder involving the central and peripheral
nervous systems, is mostly associated with unstable expansion of GAA trinucleotide repeats in the first intron of
the FXN gene, which encodes the mitochondrial frataxin protein. Since FXN was shown to be involved in
Friedreich’s ataxia in the late 1990s, the consequence of frataxin loss of function has generated vigorous debate.
Very early on we suggested a unifying hypothesis according to which frataxin deficiency leads to a vicious circle of
faulty iron handling, impaired iron-sulphur cluster synthesis and increased oxygen radical production. However,
data from cell and animal models now indicate that iron accumulation is an inconsistent and late event and that
frataxin deficiency does not always impair the activity of iron-sulphur cluster-containing proteins. In contrast,
frataxin deficiency appears to be consistently associated with increased sensitivity to reactive oxygen species as
opposed to increased oxygen radical production. By compiling the findings of fundamental research and clinical
observations we defend here the opinion that the very first consequence of frataxin depletion is indeed an
abnormal oxidative status which initiates the pathogenic mechanism underlying Friedreich’s ataxia.
Background
Friedreich’s ataxia (FA), the most prevalent form of auto-
somal recessive cerebellar ataxia in Caucasians, is charac-
terised by progressive ataxia and dysarthria [1]. The
symptoms usually become apparent around puberty,
although onset may occur much later in life (> 60 years
old). The neurological features include sensory neuropa-
thy, deep sensory impairment, signs of pyramidal tract
involvement and progressive cerebellar dysfunction. The
nonneurological manifestations vary, but among them
hypertrophic cardiomyopathy is common. Diabetes melli-
tus occurs in approximately one-third of FA patients [1].
FA therefore appears to be a rather heterogeneous disor-
der. In the vast majority of cases, it is caused by a GAA
trinucleotide repeat expansion in the first intron of the
frataxin-encoding gene (FXN), which results in decreased
gene expression and partial loss of function of the fra-
taxin protein in the mitochondrial matrix [2]. Frataxin
has been shown to interact with the iron-sulphur cluster
(ISC) assembly machinery [3] (Figure 1). Frataxin loss of
function therefore can result in ISC-containing protein
(ISP) deficiency, decreasing aconitase and mitochondrial
respiratory chain activity [4], but it also results in hyper-
sensitivity to oxidative stress [5,6] and accumulation of
iron in affected organs [7].
Except perhaps for gene-targeting therapies, to
develop rational treatments for FA, we need to better
elucidate the actual mechanism underlying the disease
pathophysiology. On the basis of recent studies of var-
ious conditions in many different organisms (from
microorganisms to humans), including human diseases
originating from mutations in genes functionally related
to FXN, we tried to reconcile the various pathogenic
manifestations resulting from frataxin depletion and
argue for a prominent and early role of impaired
responses to oxidative insults in FA.
The vicious circle hypothesis
The cellular consequences of frataxin loss of function
were initially described as faulty iron handling, impaired
ISC synthesis and increased reactive oxygen species pro-
duction [4]. We and others hypothesized that a vicious
circle might link these three abnormalities (Figure 2A)
and that targeting any of the three would consequently
* Correspondence: pierre.rustin@inserm.fr
1Inserm, U676, Physiopathology and Therapy of Mitochondrial Diseases
Laboratory, CHU - Hôpital Robert Debré, 48, boulevard Sérurier, F-75019
Paris, France
Full list of author information is available at the end of the article
Bayot et al. BMC Medicine 2011, 9:112
http://www.biomedcentral.com/1741-7015/9/112
© 2011 Bayot et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.be as effective in slowing disease progression as target-
ing one or both of the other two abnormalities.
Frataxin deficiency is not consistently associated with
impaired iron-sulphur cluster synthesis or stability
In 1997, we reported the deficiency of ISP activity as the
signature of frataxin depletion in humans [4]. Most tis-
sues investigated, including skeletal muscle, lymphocytes
and skin fibroblasts, were spared, however, and the defi-
ciency was observed only in the heart and reported later
in postmortem brain tissue. Since that initial observa-
tion, a series of remarkable works by Lill’s group [3] car-
ried out on frataxin-lacking yeast have conclusively
demonstrated that frataxin has the capacity to partici-
pate in ISC synthesis through its interaction with the
biosynthesis machinery.
However, in a number of conditions, frataxin depletion
was not found to be associated with decreased activity of
ISPs. In particular, as noted above, studies of frataxin-
depleted cultured human skin fibroblasts, circulating
lymphocytes or lymphoblastoid cell lines from FA
patients found no decrease in ISPs [4], although the fra-
taxin content was < 20% of the control value. Neverthe-
less, these cells have a phenotype that responds
abnormally to a whole range of oxidative insults [6,8,9].
Studies of Saccharomyces cerevisiae also identified condi-
tions under which, even in the total absence of frataxin, a
significant synthesis of ISCs took place [10]. Thus, ISCs
in frataxin-lacking S. cerevisiae were still synthesized
when the cultures were protected from oxygen exposure
(> 55% for 4Fe-4S clusters as compared to control yeast)
[10]. This established that the function of frataxin in ISC
synthesis and/or stability is dispensable under these con-
ditions, as it is in a number of organisms, including
A r c h a e aa n dG r a m - p o s i t i v eb a c t e r i a[ 1 1 ] ,a n dm i g h tb e
related to protection from oxygen-derived components.
Intramitochondrial iron accumulation is a late event
As early as 1997, the intramitochondrial accumulation of
iron was reported in the frataxin-lacking yeast, which led
to the suggestion that frataxin regulates the export of iron
from the mitochondrial matrix [12]. This echoed the even
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Figure 1 Frataxin function in the mitochondria. The schema illustrates the iron-sulphur cluster (ISC) biosynthesis machinery present in the
mitochondrial matrix encompassing the ISCU-NFS1 protein complex associating glutaredoxin 5 (GLRX5) with the frataxin protein. It makes use of
iron possibly delivered by the mitochondrial ferritin to synthesize ISC also distributed among several of the mitochondrial proteins (including
several membrane-bound respiratory chain components, complexes I, II and III and the matrix-soluble aconitase). In addition to its role in the
biogenesis of ISC, the frataxin protein might be associated with ISC after their synthesis. The detoxifying role of vitamin E in the mitochondrial
inner membrane is also indicated. ISP, ISC-containing protein; mt, mitochondrial.
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Page 2 of 8earlier observation of iron accumulation in postmortem
human brain tissue [7]. Because reduced iron readily trig-
gers deleterious Fenton chemistry, we and others have
proposed that iron could be instrumental in the pathophy-
siological process that results in FA [13]. However, except
for some circumstantial reports [5], attempts to detect sig-
nificant mitochondrial iron accumulation in frataxin-
depleted human fibroblasts and lymphoblasts, as well as
changes in mitochondrial labile (reactive) iron, have failed
[14]. Mitochondrial iron accumulates in frataxin-depleted
cells only as a consequence of severely diminished ISC
synthesis, resulting in amorphous, nonreactive, intramito-
chondrial precipitates of nanoparticles of ferric phosphate
[15]. Accordingly, in mouse tissues lacking frataxin, mito-
chondrial iron deposition is a late event that follows the
loss of ISPs [16]. Together these data suggest that mito-
chondrial iron accumulation is not an instrumental factor
in the early steps of FA pathogenesis.
Frataxin depletion does not cause overproduction of
superoxides
On the basis of the putative respiratory chain impair-
ment and/or the iron-associated Fenton chemistry pre-
sumably resulting from iron mishandling, it has been
inferred that frataxin depletion should result in
overproduction of oxidant species. This inference was
supported by the report of increased oxidative insult to
DNA in FA patients [17]. However, under a number of
conditions, no increase in oxidative species could be
detected, and the mitochondria from frataxin-depleted
cells (that is, fibroblasts) did not significantly produce
more superoxides (assessed using the MitoSOX Red
reagent; Invitrogen, Carlsbad, CA, USA than control
cells, and targeting superoxides in frataxin-depleted
human cells using Mn(III) tetrakis (4-benzoic acid) por-
phyrin chloride failed to restore a normal phenotype in
these cells (P Rustin, unpublished data).
Frataxin deficiency consistently results in hypersensitivity
to oxygen radicals
Numerous studies using various models have established
that partial or complete frataxin deficiency results in
varying degrees of respiratory chain impairment. Super-
oxide production by the mitochondria is mostly propor-
tional to the electron flow and to the reduction of
critical components of the chain, whereas superoxide
elimination essentially depends on superoxide dismutase
activity. The very severe impairments in respiratory
chain and Krebs cycle activity associated with the
absence of frataxin presumably result in decreased
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Figure 2 The vicious circle hypothesis revisited in Friedreich’sa t a x i a . (A) According to the vicious circle hypothesis, frataxin depletion
results in impaired iron-sulphur cluster synthesis and/or stability with intramitochondrial accumulation of reactive iron. Reactive iron promotes
Fenton chemistry, producing superoxide and hydrogen peroxide, which in turn destroys more iron-sulphur clusters. ISC, iron-sulphur cluster. (B)
In frataxin-depleted cells, deficient signalling of antioxidant defences sensitises the frataxin-free iron-sulphur clusters to reactive oxygen species.
This antioxidant sensitisation process results in intramitochondrial iron accumulation, mostly as amorphous nonreactive precipitates. ROS, reactive
oxygen species.
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Page 3 of 8superoxide production. Underestimation of the conse-
quences of complete frataxin deficiency has led to the
apparently paradoxical conclusion that oxidative stress
may not play a major role in FA pathology [18]. In con-
trast, in affected human tissues and a number of FA
models, respiratory chain activity is only partially
affected and the superoxide production machinery is
therefore largely intact. In human fibroblasts with low
frataxin content, we found a slight but consistent (<
30%) elevation in basal superoxide dismutase activity
[9], indicating that the oxidative status might be slightly
abnormal, at least under conditions where the respira-
tory chain is fully active [19]. Similarly, in contrast to
mice lacking frataxin [18], mice with partial loss of fra-
taxin show increased signs of lipoperoxidation [20].
Studies of the antioxidant pools in frataxin-depleted
cultured human cells have shown significant decreases
in reduced glutathione along with actin stress fibre dis-
organization [21], but this reduction in antioxidant
pools have little or no impact on the cells under basal
conditions. However, these cells and their iron-sulphur
p r o t e i n sh a v ee x q u i s i t es e n s i t i v i t yt oaw i d er a n g eo f
experimental oxidative insults [9], which often trigger
rapid apoptosis [5,6,8]. This hypersensitivity was found
in all frataxin-deficient cell types and organisms inde-
pendently of abnormalities in mitochondrial ISP or iron
content (Table 1). It was observed in connection with
endogenous insults (respiratory chain blockade) and
exogenous insults (various chemicals that generated oxi-
dant species) as well. These findings suggest impairment
of a set of antioxidant defences as opposed to one speci-
fic enzyme. Accordingly, impaired signalling of phase II
antioxidant defences has been observed in frataxin-
depleted human cells [9].
This impairment is related to abnormalities in the
nuclear factor erythroid 2-related factor 2 (Nrf2) tran-
scription factor, which may re s u l tf r o md i s o r g a n i z a t i o n
of the actin stress filaments and abnormalities in the
redox status of frataxin-deficient cells [9]. Concomitant
impairments in related signalling pathways for mito-
chondrial components in response to the abnormal
redox status of frataxin-depleted cells have also been
reported [22].
Lessons from clinical practice
Interestingly, myopathy without ataxia associated with
impaired ISC synthesis was described recently [23]. This
condition is due to mutation in the gene encoding the
ISC scaffold protein (ISCU) in which differential splicing
among tissues largely explains the tissue specificity [24].
Although recent data from Isaya’s group [25] show that
two frataxin isoforms do exist and have distinct func-
tional properties regarding iron storage and/or ISC
synthesis [25], expression of the protein appears wide-
spread in the organism, and both isoforms are suppo-
sedly similarly affected by GAA expansion in the gene.
Accordingly, frataxin loss of function appears to be
widespread in FA patients. Yet, the consequences are
mostly observed in the brain and the heart, and primary
myopathy is not a consistent or frequent feature of this
disease [26].
Because frataxin has been reported to interact directly
with the NFS1-ISCU protein complex during ISC bio-
synthesis [3] (Figure 1), a certain level of overlap might
Table 1 Consequences of frataxin depletion in various organisms
a
Organism Increased ROS
production/low
glutathione
Increased
peroxidation
products
Hypersensitivity to
oxidative insults
Loss of ISP
activity
Mitochondrial
iron overload
References
Saccharomyces
cerevisiae yeast
+/++ +++ +++ +++ +++ [19]
Arabidopsis
thaliana plant
+ n.d. +++ +++ ++ [69]
Caenorhabditis
elegans worm
n.d. n.d. +++ +++ n.d. [50]
Drosophila
melanogaster fly
(+) n.d. +++ +++ n.d. [70]
Mus musculus mouse
(humanised)
n.d. +++ n.d. +++ - [20]
Homo sapiens
heart
n.d. n.d. n.d. +++ ++ [4]
Homo sapiens
lymphoblasts
n.d. - +++ - - [14]
Homo sapiens skin
fibroblasts
+- +++ -- [ 9 ]
aROS: reactive oxygen species; ISP: iron-sulphur cluster-containing protein; +++: hallmark of the disease; ++: present in most cases; +: present only in a subset of
patients or late in the course of the disease; (+): reported occasionally; -: usually absent; n.d., not determined.
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mutation causes a phenotype. The absence of such over-
lap is thus not easy to reconcile with the fact that the
two proteins are involved in the same step of ISC bio-
synthesis in vivo (Table 2). A similar observation stands
true regarding glutaredoxin 5 (an assembly factor for
cellular ISC) [27] (Figure 1), as a mutation in the exon 1
of the GLRX5 gene, putatively leading to a deleterious
splicing defect, results in sideroblastic anaemia without
ataxia and no overlap with the FA phenotype [28].
Accumulation of mitochondrial iron and decreased
cytosolic iron associated with the ABCB7 mutations,
mostly missense mutations changing amino acids in the
C-terminal end of the transmembrane domain of the
protein, results in cerebellar ataxia, albeit different from
FA, and includes sideroblastic anaemia [29,30]. This
ABC transporter is involved in ISC export from the
mitochondria to the cytosol [31] (Figure 1). Yeast stu-
dies showed preserved mitochondrial ISP activity despite
intramitochondrial iron accumulation [32]. However, as
with frataxin depletion, hypersensitivity to oxidative
stress has been reported in ABCB7 mutants [33], sug-
gesting that a common mechanism resulting in impaired
handling of reactive oxygen species may be involved at
some point in both types of ataxia.
Finally, the striking similarity of the symptoms in vita-
min E deficiency and frataxin deficiency [34], both
encompassing cerebellar ataxia with inconsistent cardio-
myopathy [35], suggests similar cellular consequences of
frataxin and vitamin E depletion. Vitamin E acts chiefly
as a membrane antioxidant, in concert with ubiquinone,
and plays no role in ISC biosynthesis [36] (Figure 1).
Thus, a comparison of the various clinical phenotypes
(Table 2) is consistent with, though obviously not prov-
ing per se, the view [37] emerging from studies of var-
ious situations and models (Table 1) that frataxin
depletion results primarily in increased sensitivity to oxi-
dative stress (Figure 2B).
Discussion
Since the discovery of the gene mutation responsible for
FA, major advances have been made in our understanding
of this disease, despite the difficulties encountered in gain-
ing access to affected tissue in humans, especially the
brain. In particular, FA can now be regarded as a true
mitochondrial disease similar to a number of mitochon-
drial ataxias due to different genetic mechanisms [38]. The
respective roles of deficient respiratory chain function
(decreased ATP synthesis) and impaired oxygen handling
in the clinical course remain to be determined in most of
these diseases. However, in the case of FA, impaired oxy-
gen handling appears to be crucial in the cascade of events
determining the onset of the symptoms and fits the pro-
gressive degenerative course of the disease. Obviously,
emphasizing the role of hypersensitivity to oxygen in trig-
gering FA does not shed any light on the undisputed con-
tributory role of frataxin in ISC synthesis and/or stability
[39,40]. Yet, available data indicate that both processes can
be dissociated under a number of conditions in different
models, including humans. Unfortunately, the molecular
mechanism linking frataxin function to this hypersensitiv-
ity to oxygen is not yet established, similarly to the exact
role of the protein in ISC synthesis, which is still a matter
of intense debate. Frataxin has been claimed to activate
import of iron into the cell [41] and to chaperone iron
[42,43] or ISC [44,45] to act as a partner for [46] or inhibi-
tor of [47] ISC synthesis. How frataxin shortage in mito-
chondria results in impaired signalling of antioxidant
defences in the cell cytosol has yet to be elucidated. So far,
it is only known that frataxin deficiency in human cells
interferes with the redox status of the cell [21], thus pre-
sumably impairing the function of the Nrf2 [9] and possi-
bly PGC1a [48] transcription factors.
Hypersensitivity to oxidant insult is a consistent fea-
ture of human cells [5,6,8,9] and animal models [49,50]
with low frataxin content (Table 1). This observation
should not be confused with an increased production of
Table 2 Cardinal clinical symptoms associated with deficiencies in frataxin, vitamin E, ABCB7 (mitochondrial iron
overload), GLRX5 (impaired ISC synthesis) and ISCU (impaired ISC synthesis)
a
Clinical symptoms Frataxin deficiency Vitamin E deficiency ABCB7 deficiency GLRX5 deficiency ISCU deficiency
Ataxia +++ +++ +++ - -
Cardiomyopathy ++- - -
Diabetes mellitus + (+) - +-
Myopathy (+) (+) - - +++
Sideroblastic anaemia - - +++ +++ -
Hepatosplenomegaly - - - ++ -
Lactic acidosis (+) (+) - - +++
a+++: hallmark of the disease; ++: present in most cases; +: present only in a subset of patients or late in the course of the disease; (+): reported occasionally; -:
usually absent. Disease symptoms shared with Friedreich’s ataxia are represented using a similar grey colour.
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quently been observed and reported (in about 100
papers), which either may not be observed, especially if
respiratory chain activity is too severely depressed, or
may not be accumulated if produced at low levels.
Finally, in FA patients, oxidative markers and/or antioxi-
dant enzymes are also modified in response to frataxin
depletion [17,51-54], which was found to be an incentive
to trial antioxidant molecules in this disease [55-57].
Several ongoing clinical trials are evaluating interven-
tions that target various steps in the pathogenic process:
impaired frataxin synthesis, oxidative insults and iron
accumulation [58]. Idebenone, a short-chain coenzyme
Q10 homologue, has initially been reported to be effec-
tive (at a dosage of 5 to 20 mg/kg/day) in preventing car-
diac hypertrophy in most patients [59], while having (at
this dosage) little or no effect on the neurological
abnormalities [19]. Interestingly, while studying endo-
myocardial biopsies from a young patient with FA before
and after idebenone treatment, we found that the drug
largely restored the activity of ISPs [60]. Since idebenone
is a potent antioxidant, this finding suggests that loss of
ISP activity in vivo is due chiefly to increased oxidative
degradation, and not to impaired synthesis, of these pro-
teins. In this context, we may wonder why antioxidant
therapies (for example, idebenone, coenzyme Q10) have
such a limited impact on the neurological disease expres-
sion and/or course in FA. Indeed, recent widely based
studies carried out in Europe (the MICONOS (Mito-
chondrial Protection with Idebenone in Cardiac Or Neu-
rological Outcome Study) trial, comprising 232 patients
with 162 on idebenone, mostly adults, at 13 centres;
Andrews WT unpublished communication from the
FARA meeting in Strasbourg, France, June 2011) and in
the United States (the IONIA (Idebenone Effects on Neu-
rological International Cooperative Ataxia Rating Scale
Assessments) trial; 70 patients) [61] did not confirm the
previous reports of the beneficial effects of idebenone in
this disease. However, as mentioned by the initiators of
the MICONOS trial themselves, the results of the avail-
able studies, even if not statistically significant, still indi-
cate a trend toward a positive effect of idebenone (as
compared to placebo). A possibly underestimated factor
that might prevent the results of such studies from reach-
ing statistical significance in their relatively small cohorts
is the occurrence of responsive and unresponsive patients
reported in early FA patients treated with idebenone [59],
as has been true for a number of other mitochondrial dis-
eases [62]. Conversely, the negative conclusion of these
latter trials, mainly carried out with adults, might be
related to the age of the patients. Accordingly, even more
recently this year, an open-label extension of the IONIA
study (IONIA-E trial; 68 patients) concluded that idebe-
none may offer a therapeutic benefit to paediatric FA
patients by stabilizing overall neurological function and
improving fine motor skills and speech [63]. There is no
definite answer to this question; however, a number of
indications suggest that intervention might be much too
late. Indeed, it is a frequent observation in neurological
diseases caused by gene mutations (nuclear or mitochon-
drial) encoding mitochondrial proteins that symptoms
are subsequent to extended auto-amplifying cell death
resulting from mitochondrial dysfunction rather than
from mitochondrial dysfunction itself (for example, ATP
decrease, metabolic blockade). This can be observed in a
number of animal models where early, partial or tissue-
specific inactivation of such genes (Tfam and Aif)r e s u l t s
in a delayed neurological phenotype despite early mito-
chondrial dysfunction [64,65]. Thus, Tfam-depleted neu-
rons, despite severe respiratory chain deficiency, are
viable for one month in the mouse without showing
signs of the neurodegeneration which precedes neurolo-
gical symptoms [64]. Similarly, despite early detectable
complex I deficiency in the brain, the Harlequin mouse
with depleted Aif protein only manifests significant
symptoms after several weeks or months of life in most
individuals [65]. Likewise, frataxin gene loss of function
in FA, although it occurs early in embryogenesis, has a
neurological impact several years later. Thus, the onset of
neurological symptoms associated with impaired mito-
chondrial function might follow the loss of neurons
rather than mitochondrial dysfunction per se. Accord-
ingly, any therapy aimed at counteracting mitochondrial
dysfunction, regardless of the strategy used (modulating
gene expression, gene therapy or pharmacological ther-
apy) would be best tested if it preceded disease initiation.
Conclusions
The present compilation of recent data on the patholo-
gical cascade in FA argues in favour of continuing
experimentation with antioxidants in FA, despite the
deceptive results of the most recent idebenone clinical
trials, but care should be taken to focus on selected
cohorts of patients within the presumed therapeutic
window. Additional therapeutic strategies aimed at
counteracting hypersensitivity to reactive oxygen species
should also be developed. In keeping with this, pioglita-
zone, a peroxisome proliferator-activated receptor g
ligand that improves natural antioxidant defences
(including frataxin), is presently being under trial in our
hospital in France (two-year phase III trial ending in
2013). Other approaches aimed at increasing frataxin
levels, histone deacetylase inhibitors [66] and nonery-
thropoietic derivatives of erythropoietin [67] may also
result in decreased cellular hypersensitivity to reactive
oxygen species, as a direct correlation has been shown
between this hypersensitivity and the actual level of fra-
taxin, from depletion to overexpression [68]. We hope
Bayot et al. BMC Medicine 2011, 9:112
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Page 6 of 8that some of these promising compounds will prove
effective in halting the progression of FA.
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